nav menu
close nav
background
background

NEWS

9 August 2022

Akston Biosciences Receives U.S. Patent for Once-A-Week Human Insulin

Akston Biosciences Receives U.S. Patent for Once-A-Week Human Insulin

1 July 2022

Why Indian Pharma Must Evolve As ‘Value Creator’?

Why Indian Pharma Must Evolve As ‘Value Creator’?

24 June 2022

Strides Pharma jumps on positive outcome of COVID-19 vaccine trials

Strides Pharma jumps on positive outcome of COVID-19 vaccine trials

24 June 2022

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

1 June 2022

Akston Biosciences raising up to USD 10m to advance COVID-19 vaccine and other products, CEO says

Akston Biosciences raising up to USD 10m to advance COVID-19 vaccine and other products, CEO says

27 May 2022

Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs

Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs

12 May 2022

Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

27 April 2022

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

21 April 2022

Akston Begins Trials For Room Temperature Covid Shot As Next-Generation Vaccine Race Heats Up

Akston Begins Trials For Room Temperature Covid Shot As Next-Generation Vaccine Race Heats Up

13 April 2022

Getting through the Corona pandemic with AKS-452 vaccines

Getting through the Corona pandemic with AKS-452 vaccines